Quality of life with trimetazidine

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Trimetazidine, a metabolic agent with anti-ischemic properties, has strong evidence of efficacy and tolerability in the treatment of patients with ischemic cardiomyopathy, including subjects with chronic angina and heart failure. There is now a growing evidence that trimetazidine has also a positive impact on quality of life of these patients. This seems to be a consequence of the clinical benefits provided by trimetazidine on one hand, and of its optimal tolerability profile on the other. Benefits of trimetazidine administration include symptom relief, particularly reduction of episodes of angina and dyspnea with a resulting improvement in exercise tolerance. The clinical effectiveness of trimetazidine can alone explain its impact on quality of life in a disease, such as ischemic cardiomyopathy, where poor quality of life is strongly related to the limitation of daily living activities imposed by symptoms.

Original languageEnglish
Pages (from-to)28-31
Number of pages4
JournalHeart and Metabolism
Issue number52
Publication statusPublished - 2011

Fingerprint

Trimetazidine
Quality of Life
Cardiomyopathies
Exercise Tolerance
Activities of Daily Living
Dyspnea
Heart Failure

Keywords

  • Ischemic cardiomyopathy
  • Quality of life
  • Trimetazidine

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Quality of life with trimetazidine. / Marazzi, Giuseppe; Caminiti, Giuseppe; Volterrani, Maurizio.

In: Heart and Metabolism, No. 52, 2011, p. 28-31.

Research output: Contribution to journalArticle

@article{95b5687d37d64fd3b64efa74dcbedf67,
title = "Quality of life with trimetazidine",
abstract = "Trimetazidine, a metabolic agent with anti-ischemic properties, has strong evidence of efficacy and tolerability in the treatment of patients with ischemic cardiomyopathy, including subjects with chronic angina and heart failure. There is now a growing evidence that trimetazidine has also a positive impact on quality of life of these patients. This seems to be a consequence of the clinical benefits provided by trimetazidine on one hand, and of its optimal tolerability profile on the other. Benefits of trimetazidine administration include symptom relief, particularly reduction of episodes of angina and dyspnea with a resulting improvement in exercise tolerance. The clinical effectiveness of trimetazidine can alone explain its impact on quality of life in a disease, such as ischemic cardiomyopathy, where poor quality of life is strongly related to the limitation of daily living activities imposed by symptoms.",
keywords = "Ischemic cardiomyopathy, Quality of life, Trimetazidine",
author = "Giuseppe Marazzi and Giuseppe Caminiti and Maurizio Volterrani",
year = "2011",
language = "English",
pages = "28--31",
journal = "Heart and Metabolism",
issn = "1566-0338",
publisher = "Imprimerie Jouve",
number = "52",

}

TY - JOUR

T1 - Quality of life with trimetazidine

AU - Marazzi, Giuseppe

AU - Caminiti, Giuseppe

AU - Volterrani, Maurizio

PY - 2011

Y1 - 2011

N2 - Trimetazidine, a metabolic agent with anti-ischemic properties, has strong evidence of efficacy and tolerability in the treatment of patients with ischemic cardiomyopathy, including subjects with chronic angina and heart failure. There is now a growing evidence that trimetazidine has also a positive impact on quality of life of these patients. This seems to be a consequence of the clinical benefits provided by trimetazidine on one hand, and of its optimal tolerability profile on the other. Benefits of trimetazidine administration include symptom relief, particularly reduction of episodes of angina and dyspnea with a resulting improvement in exercise tolerance. The clinical effectiveness of trimetazidine can alone explain its impact on quality of life in a disease, such as ischemic cardiomyopathy, where poor quality of life is strongly related to the limitation of daily living activities imposed by symptoms.

AB - Trimetazidine, a metabolic agent with anti-ischemic properties, has strong evidence of efficacy and tolerability in the treatment of patients with ischemic cardiomyopathy, including subjects with chronic angina and heart failure. There is now a growing evidence that trimetazidine has also a positive impact on quality of life of these patients. This seems to be a consequence of the clinical benefits provided by trimetazidine on one hand, and of its optimal tolerability profile on the other. Benefits of trimetazidine administration include symptom relief, particularly reduction of episodes of angina and dyspnea with a resulting improvement in exercise tolerance. The clinical effectiveness of trimetazidine can alone explain its impact on quality of life in a disease, such as ischemic cardiomyopathy, where poor quality of life is strongly related to the limitation of daily living activities imposed by symptoms.

KW - Ischemic cardiomyopathy

KW - Quality of life

KW - Trimetazidine

UR - http://www.scopus.com/inward/record.url?scp=84855662843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855662843&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84855662843

SP - 28

EP - 31

JO - Heart and Metabolism

JF - Heart and Metabolism

SN - 1566-0338

IS - 52

ER -